Live Earnings: Will TransMedics (TMDX) Rally After Earnings?

Post-Earnings Move: 🟢 +6.48%

What Happened:
Revenue of $157.4M beat by ~7% and EPS of $0.92 more than doubled the $0.43 consensus. Net income jumped +186% YoY, and both service (+44%) and product (+34%) revenue showed strong double-digit growth. The company raised full-year guidance to $585M–$605M (from $565M–$585M prior).

Why the Stock Jumped:
TransMedics crushed expectations across every major financial metric and backed it with a guidance raise. Gross margin held at 61%, and free cash flow stayed positive, reassuring investors that growth is profitable and scalable. Confidence in achieving 10,000 U.S. NOP transplants by 2028 resonated.

My Take:
This was a “breakout quarter” — a combination of beat, raise, and strategic execution. Investors got margin consistency, faster platform adoption, and long-term ambition all in one call. TMDX remains volatile, but bulls will see this quarter as a turning point toward durable compounding.

Well, it looks like investors really like what they see from TransMedics’ Q2 earnings. Shares are up 6% after hours.

TMDX | TransMedics Q2’25 Earnings Highlights:

• Adj. EPS: $0.92 [✅]; UP +25% YoY
• Revenue: $157.4M [✅]; UP +38% YoY
• Net Income: $34.9M [✅]; UP +186% YoY
• Gross Margin: 61%
• Operating Expenses: $60.0M; UP +6% YoY
• Cash: $400.6M

Outlook:

• Revenue: $585M to $605M [✅]
  • The raised guidance reflects a 35% growth at the midpoint compared to the prior year revenue.
  • This adjustment is based on the strong performance in the first half of the year and increased utilization of the Organ Care System (OCS).

Q2 Segment Performance:

• Net Product Revenue: $96.1M [✅]; UP +34% YoY
• Service Revenue: $61.3M [✅]; UP +44% YoY

Other Key Q2 Metrics:

• Adj. Operating Income: $36.6M; UP +192% YoY
• R&D Expenses: $15.9M; UP +15% YoY
• SG&A Expenses: $44.1M; UP +3% YoY
• Effective Tax Rate: 5.0% (vs. 5.0% YoY)

CEO Commentary:

• Waleed Hassanein, MD: “We are proud to report another strong quarter, marked by profitable year-over-year revenue growth of 38%. Our consistent performance across all areas of the business reflects the successful execution of our strategy, the differentiated value our OCS and NOP platforms, and our unique leadership position in the transplant market. Looking ahead, we are confident in our strategy and remain laser focused on achieving and surpassing the target of 10,000 US NOP transplants in 2028, while ramping up investments to drive the next several waves of growth aimed at delivering significant top-and bottom-line growth for our business.”

Strategic Updates:

• Received conditional Investigations Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the Next-Gen OCS ™ Lung trial.
• Launched first-in-class OCS NOP digital ecosystem, NOP ACCESS ™, across major NOP ™ transplant programs across the U.S.

EPS of $.92, a significant beat of expectations.

Revenue beats by 7% (came in at $157.4 million)

Shares first dropped but are now up 2%.

We’re one hour until the closing bell and TransMedics shares just steeply declined.

If you’re watching and concerned, just keep in mind that the downturn coincided with a broader market sell-off after Fed Chair Jerome Powell said the Fed hasn’t made a decision on a September rate cut.

Shares are still up 1.25% on the day.

TransMedics is obviously a growth story, but what kind of growth does Wall Street foresee in the coming years? Here’s a look at Wall Street’s consensus revenue estimates for the coming years:

• 2025: $582 million
• 2026: $701 million
• 2027: $820 million
• 2028: $981 million
• 2029: $1.124 billion

By 2029, GAAP EPS estimates reach $4.39. As a comparison, Wall Street expects the company to deliver $1.86 of GAAP EPS this year.

As we discussed earlier, Wall Street was very pleased with TransMedics’ last earnings. The company beat Q1 earnings and revenue expectations, and also issued strong 2025 guidance. Let’s look at what Wall Street expects when the company reports after the bell:

• Revenue: $147.74 million
• Adjusted EPS: $.43
• Free Cash Flow: $13.2 million
• Gross Margin: 60.89%

Looking ahead to Q3, Wall Street expects:

• Revenue: $141.62 million
• Adjusted EPS: $.30

Last quarter, the company guided to revenue of $575 million at the midpoint this year and Wall Street is currently expecting slightly more than that guidance. Street expectations for 2025 revenues currently stand at $582 million.